1246765-51-4

Upstream product

• 65515-32-4 methyl 6-chloro-2-methoxypyridine-3-carboxylate 
• 65515-28-8 methyl 2,6-dichloronicotinate 
• 2931-23-9 ethyl 3-cyclopentyl acrylate 
• 872-53-7 cyclopentanealdehyde 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 1246765-27-4 methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate 
• 1246765-04-7 4-(3-chloro-5-cyclopentyl-4,5-dihydro-1H-pyrazol-1-yl)-2-methylbenzonitrile 
• 1246765-08-1 4-(5-cyclopentyl-3-oxopyrazolidin-1-yl)-2-methylbenzonitrile 

Downstream Products

• 1246765-52-5 (R)-methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-54-7 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid 

Relevant academic research and scientific papers

Synthesis and cross coupling of a highly substituted 2-pyridylboronate: Application to the large scale synthesis of a mineralocorticoid antagonist

The large scale synthesis of functionalized 2-pyridylboronate 8 and optimization of its Suzuki-Miyaura coupling to chloropyrazoline (R)-7 to provide a scalable synthesis of mineralocorticoid antagonist (R)-1 is described.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.